Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study

Journal:
The Lancet Oncology
Published:
DOI:
10.1016/s1470-2045(25)00158-5
Affiliations:
24
Authors:
25
Go to article
Institutions Authors Share
Pfizer, United States of America (USA)
4.000000
 0.16
Clinical Outcomes Solutions Ltd., United States of America (USA)
2.000000
 0.08
Astellas US LLC, United States of America (USA)
2.000000
 0.08
Klinikum Stuttgart, Germany
1.000000
 0.04
OPEN Health, United States of America (USA)
1.000000
 0.04
Merck - Rahway, United States of America (USA)
1.000000
 0.04
Netherlands Cancer Institute (NKI), Netherlands
1.000000
 0.04
Huntsman Cancer Institute at the University of Utah (HCI), Utah, United States of America (USA)
1.000000
 0.04
Cleveland Clinic, United States of America (USA)
1.000000
 0.04
Virgen del Rocío University Hospital, Spain
1.000000
 0.04
IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Italy
1.000000
 0.04
Asan Medical Center (AMC), South Korea
1.000000
 0.04
Princess Margaret Cancer Centre, U of T, Canada
1.000000
 0.04
Icahn School of Medicine at Mount Sinai (ISMMS), MSHS, United States of America (USA)
1.000000
 0.04
Queen Mary University of London (QMUL), United Kingdom (UK)
1.000000
 0.04
Centre Léon Bérard (CLB), France
1.000000
 0.04
Yale Cancer Center, United States of America (USA)
1.000000
 0.04
St. Marianna University School of Medicine, Japan
1.000000
 0.04
Charité - University Medicine Berlin, Germany
0.500000
 0.02
Institute Gustave-Roussy (IGR), France
0.500000
 0.02
University of Paris-Saclay, France
0.500000
 0.02
Medical University of Vienna (MUW), Austria
0.500000
 0.02
Interested in Oncology and Carcinogenesis?